A study to investigate the safety and efficacy of SAR446523 injected subcutaneously in adult participants with relapsed/refractory myeloma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511667-28-00

Acronym

TED18162

Enrollment

Registered

2024-12-09

Start date

2025-07-21

Completion date

Unknown

Last updated

2025-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasma cell myeloma refractory

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026